Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
2.
Diabetes Res Clin Pract ; 154: 17-26, 2019 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-31228493

RESUMEN

AIMS: We examined the longitudinal association between change in body composition directly measured by computed tomography (CT) and future insulin sensitivity. METHODS: This was a prospective study with 10 years of follow-up with 297 Japanese-American without diabetes. Intra-abdominal fat area (IAFA) and abdominal subcutaneous fat area (SCFA), and thigh SCFA were measured by CT. Insulin sensitivity was calculated by HOMA-IR and the Matsuda index. RESULTS: Baseline and change in IAFA were significantly and independently associated with change in HOMA-IR and Matsuda index during follow-up. In multivariate analysis, IAFA and 10-year change in IAFA (Δ IAFA) was significantly and positively associated with 10-year HOMA-IR (p < 0.001) and significantly and negatively associated with 10-year Matsuda index (p < 0.001). The association with Matsuda index though was non-linear and best modeled as a quadratic function (Δ IAFA +â€¯Δ IAFA2). No significant associations in multivariate analyses were seen between thigh SCFA and insulin sensitivity or abdominal SCFA and HOMA-IR but an increase in abdominal SCFA was associated with diminished insulin sensitivity measured by the Matsuda index. CONCLUSIONS: An increase in visceral adiposity predicts diminished insulin sensitivity over 10 years of follow-up independent of the size of this adipose depot at baseline.


Asunto(s)
Adiposidad , Asiático/estadística & datos numéricos , Resistencia a la Insulina , Grasa Intraabdominal/diagnóstico por imagen , Grasa Subcutánea Abdominal/diagnóstico por imagen , Muslo/diagnóstico por imagen , Tomografía Computarizada por Rayos X/métodos , Femenino , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Factores de Riesgo
3.
Transplantation ; 102(4): 632-639, 2018 04.
Artículo en Inglés | MEDLINE | ID: mdl-29215460

RESUMEN

BACKGROUND: Few studies have directly compared preemptive therapy (PET) and antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in CMV seropositive (R+) orthotopic liver transplant (OLT) recipients. METHODS: We prospectively assessed CMV disease and clinical outcomes among 160 consecutive R+ OLT recipients who received PET (weekly plasma CMV PCR for 3 months, oral valganciclovir 900 mg twice daily for CMV viremia >250 IU/mL, until 2 consecutive negative weekly PCR results) and compared them with a historical cohort of 156 R+ recipients who received AP (valganciclovir, 900 mg daily for 3 months). RESULTS: Patient characteristics were similar between PET and AP cohorts (P > 0.05 all comparisons). In the PET group, 24% (39/160) developed CMV viremia greater than 250 IU/mL at a median of 42 (range, 7-93) days post-OLT. CMV monitoring adherence in the PET cohort was 85% (1488/1760 required tests) and 86% (30/36) initiated PET within 3 days of the CMV result. By 12 months post-OLT, the incidence of CMV disease, acute allograft rejection, major infection, or death in the PET and AP cohorts was not significantly different: 2% versus 2%, 19% versus 16%, 10.5% versus 10.8%, and 5% versus 8%, respectively (P > 0.05 all comparisons). The estimated proportion of drug-exposed patients and average antiviral drug exposure were significantly lower with PET versus AP: 24% versus 100%, P < 0.001, and 15.8 versus 81 g per patient, P < 0.001, respectively. CONCLUSIONS: PET is feasible in a nonresearch setting and is associated with similar CMV disease rates and other clinically relevant outcomes to AP in CMV seropositive liver transplant recipients.


Asunto(s)
Anticuerpos Antivirales/inmunología , Antivirales/administración & dosificación , Infecciones por Citomegalovirus/prevención & control , Citomegalovirus/efectos de los fármacos , Trasplante de Hígado , Infecciones Oportunistas/prevención & control , Valganciclovir/administración & dosificación , Administración Oral , Adulto , Anciano , Anticuerpos Antivirales/sangre , Antivirales/efectos adversos , Citomegalovirus/genética , Citomegalovirus/inmunología , Citomegalovirus/patogenicidad , Infecciones por Citomegalovirus/sangre , Infecciones por Citomegalovirus/inmunología , Infecciones por Citomegalovirus/virología , Esquema de Medicación , Estudios de Factibilidad , Femenino , Humanos , Huésped Inmunocomprometido , Inmunosupresores/efectos adversos , Trasplante de Hígado/efectos adversos , Masculino , Persona de Mediana Edad , Infecciones Oportunistas/sangre , Infecciones Oportunistas/inmunología , Infecciones Oportunistas/virología , Estudios Prospectivos , ARN Viral/genética , Factores de Tiempo , Resultado del Tratamiento , Valganciclovir/efectos adversos , Carga Viral , Adulto Joven
4.
Transpl Infect Dis ; 19(3)2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28295973

RESUMEN

Alternaria species have been reported as a rare cause of fungal infection in organ and stem cell transplant recipients, but to date, no reports have been published of infection in humans caused by Alternaria rosae. Here, we report cutaneous A. rosae infection in a 66-year-old farmer with a history of primary myelofibrosis who had undergone allogeneic unrelated donor hematopoietic stem cell transplantation. Forty-nine days post transplant, he presented with a nodule on the thumb with no findings suggestive of disseminated infection. Pathology, culture, and molecular speciation showed the nodule was caused by cutaneous A. rosae. He had been on voriconazole as antifungal prophylaxis, but was found to have a subtherapeutic voriconazole level. He was switched to posaconazole based on published in vitro data showing its superior efficacy in Alternaria treatment. Susceptibility testing showed that the A. rosae isolate was indeed susceptible to posaconazole. His cutaneous lesion remained stable, but he died from respiratory failure secondary to lobar pneumonia. At lung autopsy, A. rosae was not identified in the lungs. We believe this to be the first published report, to our knowledge, of A. rosae infection in humans.


Asunto(s)
Alternaria/patogenicidad , Alternariosis/microbiología , Antifúngicos/uso terapéutico , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Feohifomicosis/microbiología , Mielofibrosis Primaria/terapia , Lesión Renal Aguda/inducido químicamente , Lesión Renal Aguda/terapia , Aciclovir/uso terapéutico , Anciano , Alternaria/aislamiento & purificación , Profilaxis Antibiótica/métodos , Quimioterapia Combinada/efectos adversos , Quimioterapia Combinada/métodos , Resultado Fatal , Enfermedad Injerto contra Huésped/tratamiento farmacológico , Mano/diagnóstico por imagen , Humanos , Terapia de Inmunosupresión/efectos adversos , Terapia de Inmunosupresión/métodos , Levofloxacino/uso terapéutico , Imagen por Resonancia Magnética , Masculino , Pruebas de Sensibilidad Microbiana , Senos Paranasales/diagnóstico por imagen , Neumonía/complicaciones , Prednisona/uso terapéutico , Insuficiencia Respiratoria/complicaciones , Esporas Fúngicas/aislamiento & purificación , Esporas Fúngicas/patogenicidad , Trasplante Homólogo/efectos adversos , Triazoles/uso terapéutico , Voriconazol/uso terapéutico
5.
Endocrinology ; 158(2): 293-303, 2017 02 01.
Artículo en Inglés | MEDLINE | ID: mdl-27870582

RESUMEN

Islet endothelial cells produce paracrine factors that support ß-cell function and growth. Endothelial dysfunction underlies diabetic microvascular complications; thus, we hypothesized that in diabetes, islet endothelial cells become dysfunctional, which may contribute to ß-cell secretory dysfunction. Islets/islet endothelial cells were isolated from diabetic B6.BKS(D)-Leprdb/J male (db/db) mice, treated with or without the glucose-lowering agent phlorizin, or from C57BL/6J mice fed a high-fat diet for 18 weeks and appropriate controls. Messenger RNA (mRNA) and/or the protein levels of the cell adhesion molecule E-selectin (Sele), proinflammatory cytokine interleukin-6 (Il6), vasoconstrictor endothelin-1 (Edn1), and endothelial nitric oxide synthase (Nos3; Nos3) were evaluated, along with advanced glycation end product immunoreactivity. Furthermore, an islet endothelial cell line (MS-1) was exposed to diabetic factors (glucose, palmitate, insulin, and tumor necrosis factor-α) for six days. Conditioned media were collected from these cells, incubated with isolated islets, and glucose-stimulated insulin secretion and insulin content were assessed. Islet endothelial cells from db/db mice exhibited increased Sele, Il6, and Edn1 mRNA levels, decreased Nos3 protein, and accumulation of advanced glycation end products. Phlorizin treatment significantly increased Nos3 protein levels but did not alter expression of the other markers. High-fat feeding in C57BL/6J mice resulted in increased islet Sele, Il6, and Edn1 but no change in Nos3. Exposure of islets to conditioned media from MS-1 cells cultured in diabetic conditions resulted in a 50% decrease in glucose-stimulated insulin secretion and 30% decrease in insulin content. These findings demonstrate that, in diabetes, islet endothelial cells show evidence of a dysfunctional phenotype, which may contribute to loss of ß-cell function.


Asunto(s)
Endotelio/fisiopatología , Insulina/metabolismo , Islotes Pancreáticos/fisiopatología , Animales , Biomarcadores/metabolismo , Dieta Alta en Grasa/efectos adversos , Células Endoteliales/metabolismo , Glucosa , Secreción de Insulina , Masculino , Ratones , Ratones Endogámicos C57BL , Florizina
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...